Imagine a fast-track testing center for medicines, like a multi-lane highway instead of a single road. Instead of testing one drug at a time, this setup allows researchers to test several different antiviral candidates simultaneously to see which one works best against Lassa fever. It's designed to quickly find a safer alternative to the current treatment, which is often toxic and expensive.
Lassa fever lacks safe, effective, and affordable treatments, with the current standard (ribavirin) being toxic and potentially ineffective. This leads to high mortality and significant socio-economic burdens in West Africa.
A GCP-compliant adaptive clinical platform trial for phase II-III testing of antiviral drugs and a network of trained research sites in West Africa.
If you are a drug developer dealing with the high cost and risk of late-stage trials — this project developed an adaptive platform trial that can test repurposed and new drug candidates for Lassa fever. This allows for faster evaluation of efficacy and safety in the most affected regions, where 80% of global cases occur.
If you are a CRO dealing with the lack of GCP-compliant infrastructure in West Africa — this project developed a network of trained sites and laboratories. This provides a ready-to-use operational bridge for conducting phase II-III trials in Nigeria and neighboring countries.
If you are a provider dealing with the difficulty of delivering specialized care in outbreak zones — this project developed a capacity-building model for medical care and diagnostics. This creates a structured environment for deploying new therapies to patients who currently face a 12% in-hospital mortality rate.
Based on available project data, the EU contribution is EUR 8,000,000, but the specific cost for commercial access to the platform is not mentioned.
The project establishes a phase II-III clinical platform trial, which is the standard scale for validating drugs before mass production and market entry.
Based on available project data, the project focuses on testing repurposed and novel drugs, but specific licensing or patent agreements are not detailed.
The project specifically implements a GCP-compliant (Good Clinical Practice) trial to ensure international regulatory standards are met.
The project period runs from 2023-07-01 to 2028-06-30, indicating a 5-year window for trial implementation and results.
The consortium is heavily research-oriented, consisting of 15 partners across 10 countries. It is composed of 5 universities and 6 research institutions, with 4 other organizations. Notably, there are 0 industry partners and 0 SMEs, indicating that the project is currently in a public-health and academic validation phase rather than a commercial one.
Contact Universite de Bordeaux regarding the adaptive platform trial results.
Contact us to identify potential antiviral candidates for this platform.
